On the global scale, the HIV-1 epidemic is primarily driven by heterosexual transmission, accounting for the vast majority of the currently 33 million people infected with this lethal pathogen (1). Because more than 96% of new infections occur in low- and middle-income countries, it is expected that the successful clinical development of antiretroviral drug-based microbicides may not only significantly slow sexual transmission of HIV-1 but may also provide a simple and affordable prevention method, particularly for application in resource-poor settings (reviewed in refs. 2 and 3).

During the process of identifying natural agents that interfere with HIV-1 replication, Münch et al. (4) recently identified a peptide fraction in human semen (SE) that consistently enhanced HIV-1 infection. The major enhancing activity was correlated with the presence of a peptide derived from the internal region of prostatic acidic phosphatase (PAP) (4), a protein that is produced by the prostatic gland and secreted in large quantities (1–2 mg/mL) into SE (5). Interestingly, the ability of this peptide, corresponding to PAP amino acid residues 248–286 (PAP248–286), to boost infectivity of a broad range of HIV-1 strains, including X4-, R5-, and dual-tropic isolates as well as group M and O strains, depended on its unexpected capacity to form β-sheet-rich amyloid fibrils (4). Although their exact mode of action is largely unknown, these fibrils, termed semen-derived enhancer of virus infection (SEVI), supposedly capture virions and attach them to the surface of target cells, thereby enhancing receptor-mediated virus–host cell fusion (discussed in ref. 6). Apparently, the positively charged SEVI decreases charge–charge repulsions that exist between virions and host cells (7). Thus, SE-derived, fibril-forming PAP fragments may strongly promote HIV transmission during sexual intercourse, particularly when low quantities of infectious virus are available to cross the mucosal barrier (reviewed in refs. 2 and 8). Moreover, the action of SEVI may be detrimental to the successful development of antiretroviral microbicides, a field of clinical research that currently faces various technical challenges (9). For these reasons, it is fair to assume that the inclusion of a SEVI inhibitor into an antiretroviral microbicide-based regimen may improve the potential of such a strategy to prevent sexual transmission of HIV-1.

Many highly diverse proteins are able to self-assemble into amyloid fibrils (10, 11), a process that is frequently associated with serious neurodegenerative disorders, such as Parkinson’s disease and Alzheimer’s disease (12, 13). A recent study was conducted to investigate whether small-molecule inhibitors can interfere with amyloid formation and, in particular, it has been demonstrated that the polyphenol epigallocatechin-3-gallate (EGCG) efficiently inhibits amyloid fibrillogenesis (14). EGCG is the major catechin in green tea and has been ascribed to exert various antitumorigenic, antioxidative, antibacterial, and antiviral effects (for reviews, see refs. 15–17). Because of its antifibrillogenic properties (14), we analyzed the potential of EGCG to target PAP248–286-derived fibrils and to interfere with SE-mediated enhancement of HIV-1 infection in the present study.

Results and Discussion

Effects of the Green Tea Catechin EGCG on PAP-Derived Amyloid Fibrils. The capacity of a synthetic PAP248–286 peptide to form amyloid fibrils was analyzed in the presence or absence of various concentrations of EGCG. Fibril formation of the freshly dissolved peptide (1 and 5 mg/mL in PBS) was initiated by agitation at 37 °C and monitored over time by Congo red staining, a standard method to detect amyloid fibrils (18). In agreement with previous data (4), fibril formation was easily observed at both peptide concentrations in absence of EGCG (Fig. 1A). Further inspection of the data revealed that EGCG interfered with fibrillogenesis in a dose-dependent fashion. The ratio of PAP248–286 to EGCG clearly affected the inhibitory capacity of EGCG in these experiments (Fig. 1A, compare Upper and Lower). High inhibitor levels (10 and 20 mM EGCG) completely abrogated the formation of fibrils at both inhibitor concentrations. Furthermore, when EGCG was present in the reaction at lower concentrations (i.e., 1 and 5 mM), newly formed fibrils were apparently degraded over time (Fig. 1A).

To analyze this effect further, we next exposed preformed PAP248–286 fibrils, which were generated in the absence of inhibitor, to various concentrations of EGCG. Again, the status of fibrillogenesis was determined over time by Congo red staining. As shown in Fig. 1B, SEVI (5 mg/mL) was highly stable over a time period of 48 h. Obviously, fibril formation even...
slightly increased within the initial 3 h of incubation. In sharp contrast, however, addition of EGCG to the preformed amyloid fibrils apparently triggered their degradation, which was again observed in a dose-dependent manner. As expected, control reactions, in which PBS only (solvent for EGCG) or EGCG only (10 mM) was analyzed, did not score in this experiment.

We next wanted to confirm that our SEVI samples are indeed able to promote HIV-1 infection. For this, various concentrations of SEVI were preincubated with HIV-1 strain NL4/3 particles for 20 min in a small volume. Subsequently, this virus/SEVI mixture was used to infect Jurkat 1G5 cells, which contain a stably integrated HIV-1 LTR-luciferase construct (19). Thus, infectability of these T cells can be quantified by measuring luciferase activity. At 24 h after infection, the respective analyses revealed the expected SEVI-mediated enhancement of HIV-1 infection, clearly reaching an optimum in these cells at a SEVI concentration of 250 μg/mL (Fig. 1C). The monitoring of cellular metabolic activity, as measured by alamarBlue assay, demonstrated that SEVI did not induce any detectable toxic effect on cellular viability in Jurkat 1G5 cells at these drug concentrations (Fig. 1D).

Despite the fact that the polyphenol EGCG is a major constituent of green tea (17), and is therefore generally recognized as safe for human consumption, we next analyzed potential undesired effects of EGCG on the viability of uninfected 1G5 cells. As shown in Fig. 1E, EGCG induced no deleterious effect in these cells, even at 2.5 mM, the highest concentration tested.

To more directly monitor the action of EGCG on SEVI, we next performed analyses at the ultrastructural level by using an ultrathin sectioning technique in combination with transmission electron microscopy. Solutions of SEVI or EGCG were encapsulated in capillary microtubes (200-μm diameter; Fig. 2), fixed

Fig. 1. EGCG targets synthetic PAP248–286-derived amyloid fibrils. (A) Amyloid fibrils were formed by agitation of the fresh PAP248–286 solutions (1 and 5 mg/mL) at 37 °C. Fibrillar aggregates were exposed to various concentrations of EGCG (○, 20 mM; ▲, 10 mM; ■, 5 mM; and ▲, 1 mM) and detected by Congo red staining at the indicated time points. Addition of PBS alone (solvent for EGCG) served as negative control (×). (B) Preformed PAP248–286-derived fibrils (SEVI) were treated with increasing concentrations of EGCG (▲, 1 mM; △, 2 mM; □, 4 mM; ■, 8 mM; and ▲, 10 mM) for 48 h and analyzed as before. Reactions containing EGCG alone (●, 10 mM) or PBS alone (×) served as controls. (C) HIV-1 particles (X4 strain NL4/3) were preincubated for 20 min with or without the indicated concentrations of SEVI. Subsequently, Jurkat 1G5 luciferase indicator cells were exposed to the respective virus/SEVI mixtures for 5 h. At 24 h after infection, RLU/s was determined. Error bars represent three independent experiments. (D) Cellular metabolic activity was tested in uninfected Jurkat 1G5 cells by alamarBlue assay after 5 h of exposure to the indicated concentrations of SEVI. (E) Viabilities of uninfected Jurkat 1G5 cells were determined after 5 h exposure to the indicated EGCG concentrations as before.
in situ, dehydrated, and embedded for subsequent staining of ultrathin sections and micrograph acquisition. As shown, a 10 mM solution of the polyphenol EGCG (molecular weight, 458.37) formed small aggregates, whereas significantly larger, typical fibrillary structures were observed in instances of SEVI at a concentration of 5 mg/mL (Fig. 1A and B, respectively). To next visualize the action of EGCG on SEVI, sealed microtubes filled with dissolved SEVI fibrils were placed into a chamber filled with a solution of 10 mM EGCG and subsequently incubated over time, allowing the EGCG molecules to diffuse from the outside into the lumen of the tube. After incubation for 12 h and 60 h, the tubes were fixed, and samples were processed as before. The SEVI fibrils appeared to remain largely unaffected by EGCG after an incubation period of 12 h, although EGCG aggregates already covered the surface of the SEVI fibrils, which is particularly apparent at higher magnification (Fig. 2C). In sharp contrast, however, after incubation for 60 h, all SEVI-specific amyloid fibrils were extensively degraded (Fig. 2D), as visualized by the low contrast of the SEVI residues, directly confirming the data obtained before by Congo red staining. Thus, the combined experiments demonstrated that the polyphenol EGCG targets PAP248–286-derived amyloid fibrils.

EGCG Inhibits the Activity of PAP248–286-Specific Amyloid Fibrils. It was earlier reported that EGCG interferes with HIV-1 replication (20, 21), and various antiviral mechanisms of EGCG were suggested, including inhibition of glycoprotein of Mr 120,000 (gp120)–CD4 interaction (22, 23) and direct blocking of envelope gp41-mediated membrane fusion (24). Therefore, we next wanted to analyze the potential antiviral effect of EGCG in the absence of SEVI. As shown in Fig. 3A, even at 2.5 mM, no significant antiviral EGCG effects on de novo infection were observed in HIV-1 NL4/3-infected Jurkat 1G5 cells. It was not surprising that no cellular toxicity was detectable in these cell cultures (Fig. 3A, red plot), particularly when the results of the cell viability tests performed before were also considered (Fig. 1D and E).

Because EGCG apparently degrades SEVI, we next wanted to test whether EGCG indeed inhibits the infectivity-enhancing action of these amyloid fibrillary aggregates. We therefore again infected 1G5 cells with either the HIV-1 NL4/3 strain or the multiresistant BE4 isolate and monitored infectability by measuring luciferase activity as before. HIV-1 BE4 is a highly active antiretroviral therapy (HAART)-resistant virus with high-level resistance to multiple inhibitors of viral protease and reverse transcriptase (25). As described before, prior to infection the respective input viruses were preincubated for 20 min with SEVI (250 pg/mL) together with the concentrations of EGCG analyzed before to be nontoxic in these cells (Fig. 1E). These experiments confirmed again the infectivity-enhancing properties of SEVI and demonstrated that EGCG is indeed capable of effectively counteracting the activity of PAP248–286-derived fibrils in a dose-dependent fashion (Fig. 3B). In fact, at the highest concentration tested (2.5 mM), EGCG almost com-
Fig. 3. The green tea catechin EGCG inhibits SEVI-mediated HIV infection. (A) Jurkat 1G5 cells were infected with HIV-1 NL4/3 in presence of the indicated concentrations of EGCG. The rate of infection was monitored by measuring the luciferase activity in the respective cell cultures (indicated as RLU/s; bars), and cell viabilities were determined by alamarBlue assay (red plot) 24 h after infection. (B) HIV-1 NL4/3 or the multiple antiretroviral drug-resistant virus isolate BE4 was preincubated for 20 min with 50 μg of SEVI and the indicated concentrations of EGCG. Using this mixture, 1G5 cells were subsequently infected for 5 h. At 24 h after infection, luciferase activity was measured as before. (C) Constant amounts (2.5 mM) of EGCG or GC were incubated together with SEVI (5 mg/mL) for the indicated time periods. The degradation of SEVI in each reaction was monitored by Congo red staining (EGCG: black plot; GC: green plot). Subsequently, equal aliquots of each reaction were used to infect 1G5 cells with HIV-1 NL4/3. The respective cultures were assayed as before (EGCG: black bars; GC: green bars).

EGCG Interferes with SE-Mediated Enhancement of HIV-1 Infection.

To this point, we demonstrated that EGCG can efficiently suppress the action of SEVI that has been generated in vitro. However, any potential therapeutic application of EGCG (or of related compounds) depends on its ability to inactivate the infectivity-enhancing capacity of human SE. Thus, to more closely mirror the in vivo situation, we now included different human SE samples in our analyses.

It has been reported recently that addition of undiluted human SE might be toxic to cultured cells (4). Thus, we first investigated the infectivity-enhancing qualities of a serial dilution of a randomly selected human SE sample (SE#1). Infection of TZM-bl cells (26) with HIV-1 NL4/3 demonstrated that none of the SE#1 dilutions (1:2 to 1:32 in PBS/antibiotics) induced cellular toxicity (Fig. 4A, red plot), and that application of the 1:4 dilution in particular resulted in maximal infection of these cells (Fig. 4A). Subsequently, additional 1:4 dilutions of independent SE samples (SE#s 2–6) were compared side by side with SE#1 by using the same experimental setup (Fig. 4B). Inspection of the corresponding results indicated that individual human SE samples may vary considerably with respect to their HIV-1 infectivity-boosting properties (e.g., compare SE#s 4 and 5 in Fig. 4B). Nevertheless, the majority of these random samples significantly increased virus infection compared with the control experiment in which SE was omitted.

Then, the effect of EGCG on preventing SE-mediated enhancement of HIV-1 infection was tested on all SE samples essentially as described before. This series of experiments demonstrated that the SEVI inhibitor EGCG also efficiently abrogated the infectivity-enhancing properties of human SE in the absence of significant cellular toxicity (for SE#s 1 and 2, see Fig. 4A).
EGCG sensitivity (e.g., compare SEs 4 and 5 in Fig. S4), which appear to exist between the various SE samples with respect to infectivity-enhancing properties. Previous studies on the anti-polyphenol EGCG targets PAP248–286-derived amyloid fibrils that are present in the individual samples.

The data presented in previous reports showing that EGCG inhibits HIV-1 by directly interacting with CD4 and/or HIV-1 Env (22–24) may provide an additional antiviral benefit with respect to the usage of EGCG as a component of future microbicides. In the present study, the pronounced inhibitory activity of EGCG on HIV-1 infectivity was mainly based on its ability to degrade SEVI. Nevertheless, at high drug concentrations, virus infectivity was in some experiments (e.g., Figs. S1 and S3) reduced to below that of the corresponding control experiment lacking SEVI. This may indeed reflect a direct effect of EGCG on the CD4 receptor and/or the viral glycoproteins.

Taken together, the polyphenol EGCG, a natural ingredient of green tea, may be a valuable and cost-efficient inhibitor of SE-mediated enhancement of virus infection, and hence of sexual transmission of HIV-1.

Materials and Methods

Reagents. The green tea catechins, EGCG and GC, were obtained from Sigma–Aldrich, and stock solutions of 100 mM or 50 mM, respectively, were prepared in PBS. Aliquots of various dilutions were stored at –20 °C.

Amyloid Fibril Formation by PAP248–286 and Photometric Detection. Synthetic peptides corresponding to PAP (European Molecular Biology Laboratory accession no. AAB60640) amino acid residues 248–286 (PAP248–286) were obtained from Davids Biotechnologie and Bachem. Lyophilized peptides were resuspended in PBS at a stock concentration of 10 mg/mL, and aliquots were stored at –20 °C. Fibril formation by the freshly dissolved peptide (1 or 5 mg/mL) was initiated by agitation at 37 °C and 1,200 rpm for 2–3 days (i.e., until the solution became turbid) by using an Eppendorf thermomixer. Formation of amyloid structures was routinely monitored by mixing 5-μL aliquots of the respective reaction batch with 100 μL of Congo red solution (20 μg/mL in PBS; Sigma). The solution was incubated for 10 min at ambient temperature and centrifuged for 5 min at 20,800 × g in an Eppendorf centrifuge 5417R. Supernatants were discarded, the pellets were dissolved in 100 μL of DMSO, and fibril formation was determined at OD490–650 nm using an ELISA reader.

Treatment of SE. SE samples were donated by healthy volunteers, diluted with equal volumes of PBS containing 100 units/mL penicillin, 100 μg/mL streptomycin, and 50 μg/mL gentamycin (Gibco), and stored at –20 °C.

Analysis of Cellular Toxicity. Cell viability was analyzed by measuring cellular metabolic activity using the alamarBlue redox indicator (Sero tec) in accordance with the manufacturer’s protocol.

Cell Cultures and HIV Infection Experiments. Viruses were produced as described in the SI Materials and Methods. The suspension cell line 1G5 was cultured in RPMI medium 1640 containing 10% FCS (PanSystems) and antibiotics (penicillin and streptomycin). 1G5 cells are Jurkat derivatives containing a stably integrated HIV-LTR-firefly luciferase construct (19). Before infection, 50 ng of p24 antigen of the respective virus stock, 50 μg of PAP248–286-derived amyloid fibrils (SEVI), and various concentrations of EGCG, GC, or PBS (negative control) were incubated in a sterile reaction tube for 20 min using an Eppendorf thermomixer at 37 °C and 800 rpm. Thereafter, the respective mixtures were added to 10^5 1G5 cells and further incubated in a volume of 200 μL of 37 °C and 5% CO2. Control experiments omitted the input virus, SEVI, or EGCG. After a 5-h incubation period, cells were washed once with PBS, and the cell pellet was resuspended in 1 mL of medium and further cultured in 24-well plates. At 24 h after infection, cell cultures were divided. One half was used to analyze cell viability. The cells of the remaining half were lysed in 100 μL of passive lysis buffer, and luciferase activity was measured as relative light units per second (RLU/s) according to the manufacturer’s protocol (Promega).

Primary HIV-1 isolates were isolated in 4 × 10^5 TZM-bl cells essentially as described before. The TZM-bl cell line allows the quantification of HIV infectivity.
tion either via an integrated Tat-responsive β-galactosidase or firefly luciferase reporter expression cassette (26). Likewise, TZM-bl cells were also used to investigate the infectivity-enhancing properties of independent human SE samples. For this, 200 μL of a 1:4 dilution of independent SE samples in PBS was mixed with 50 ng of p24 antigen of HIV-1 NL/Δ3 together with various concentrations of EGCG (total volume, 300 μL) and incubated in an Eppendorf theromixer at 37 °C and 800 rpm for 20 min. Thereafter, 30 μL of the mixtures was added to 10^6 TZM-bl cells in a volume of 100 μL and incubated at 37 °C for 3 h, washed once, and further cultured in 200 μL of DMEM (10% FCS, penicillin, and streptomycin) in a 96-well, flat-bottom plate. At 24 h after infection, virus infectivity and cell viability were determined. As before, controls omitting input virus, SE, or EGCG were also included in the experimental design.

Ficoll-isolated PBMCs from healthy donors were treated with ammonium chloride, pH 7.4, for 20 min on ice to lyse erythrocytes, washed twice with PBS, and incubated in RPMI with 5% FCS, penicillin, and streptomycin. Subsequently, PBMCs were activated by using CD3/CD28 Dynabeads (Invitrogen) according to the manufacturer’s protocol. At 24 h after stimulation, 2 × 10^6 PBMCs were pelleted, resuspended, and incubated in a volume of 250 μL together with input virus (50 ng of p24 antigen), 50 μg of SEV, and various concentrations of EGCG. As before, prior to infection input virus, SEVI and EGCG were preincubated in an Eppendorf theromixer for 20 min at 37 °C and 800 rpm. Controls omitting input virus, SEVI, or EGCG were included in the experimental design. After 5 h of incubation, cells were washed with PBS and further cultured in 1 mL of medium in a 24-well plate for another 24 h. Thereafter, one half of the PBMCs were analyzed for cell viability, and the other half of the cells were lysed with passive lysis buffer for subsequent luciferase analysis as described before.

**Electron Microscopy.** For ultrastructural analysis of the dissolved components in the transmission electron microscope (TEM), the solutions of SEVI (5 mg/mL) and EGCG (10 mM) were encapsulated in capillary microtubes and processed for ultrathin sectioning technique as already described in principle and detail (28). The microtubes (200-μm diameter) were filled with the solutions by capillary attraction and mechanically sealed at both ends by a scalpel. The dissolved components within the tubes were fixed in situ from the outside through the highly porous tube walls (molecular weight cut-off: 10 kDa) by successive immersion into 2.5% glutaraldehyde, 1% uranyl acetate, and 1% OsO4 in PBS for 30 min each, followed by dehydration in a graded series of ethanol. For ultrathin sectioning, the microtubes were embedded in EPON (Carl Roth) resin. Sections were counterstained with 2% uranyl acetate and lead citrate. Electron micrographs were acquired with a Philips CM 120 TEM at 80 kV using a Gatan Multiscan 794 Camera.

To illustrate the action of EGCG on SEVI, sealed microtubes filled with dissolved SEVI were incubated into an EGCG solution. After defined reaction times, the tubes were fixed and processed as described above.

**ACKNOWLEDGMENTS.** We thank Andrea Bunk and Niklas Beschoner for excellent technical assistance and members of the laboratory for sample donation. We are indebted to Mel Smith for critical comments on the manuscript. The following reagents were obtained through the National Institutes of Health (NIH) AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH: 1G5 cells, catalogue no. 1819, from Drs. Aguilar-Cordova and Stewart N. Davis; TZM-bl cells, catalogue no. 8129, from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme; the primary HIV-1 R5 isolate 92TH026, catalogue no. 1693 from the Joint United Nations Programme on HIV/AIDS (UNAIDS) Network for HIV Isolation and Characterization; the primary HIV-1 R5X4 isolate 93BR020, catalogue no. 2329, from Drs. Beatrice Hahn and Feng Gao, and the UNAIDS Network for HIV Isolation and Characterization. We also thank Dr. Michael Schindler (Heinrich-Pette-Institute) for pBRNL43-92TH014Luc DNA. The Heinrich-Pette-Institute is a member of the Leibniz Gemeinschaft (WGL) and is supported by the Free and Hanseatic City of Hamburg and the Federal Ministry of Health.